LUND STEVEN
Known title: Exec. Chairman of the BoardCIK: 0001033942
Associated companies
Transaction History
| NUS | ▼ Sell | Gift | 9,050 | $0 | 3/1/2023 | View on chart |
| NUS | ▼ Sell | Open Market | 14,954 | $676K | 6/23/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 2,175 | $98K | 6/23/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 400 | $18K | 6/22/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 400 | $18K | 6/22/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 3,201 | $144K | 6/21/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 3,225 | $145K | 6/21/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 500 | $23K | 6/17/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 400 | $18K | 6/17/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 200 | $9K | 6/15/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 195 | $9K | 6/15/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 11,581 | $508K | 6/13/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 1,219 | $54K | 6/13/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 35,573 | $1.6M | 6/13/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 2,927 | $130K | 6/13/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 925 | $43K | 5/18/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 21,200 | $959K | 5/16/2022 | View on chart |
| NUS | ▼ Sell | Gift | 14,935 | $0 | 5/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nu Skin: Turnaround Narrative Gains Attention
A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.
Nu Skin: Turnaround Narrative Gains Attention. A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.